Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.
The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...
On completion of the scans and tests, he said: “You have early age-related macular degeneration.” When he saw my face fall, he added: “AMD – it’s very common.” My grandmother suffered.
US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...
Vabysmo Product Monograph, December 13, 2024. 2. Song P, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, ...
Outlook Therapeutics, Inc. has announced a key development in the treatment of wet age-related macular degeneration (wet AMD) with the National Institute for Health and Care Excellence (NICE ...
Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...
Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...
Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ...
Age-related macular degeneration (AMD ... 30% of cases progress to the more severe vision loss associated with wet AMD within 10 years (1 Trusted Source Massively Parallel Screening ...